Glow-in-the-Dark endoscopy could reveal who benefits from immunotherapy
NCT ID NCT07196384
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 29 times
Summary
This early-stage study tests a new imaging method called fluorescence endoscopy to see if immunotherapy targets (PD-1 and PD-L1 proteins) are present in esophageal cancer. Fifteen participants will receive two fluorescent tracers before a routine endoscopic exam. The goal is to learn whether this technique can help doctors predict which patients will respond to immunotherapy, not to treat the cancer itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.